MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rh... (elate with increased levels of this prot...)

HOME >> BIOLOGY >> TECHNOLOGY

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

Date:10/23/2008

elate with increased levels of this protein.

MedImmune has a preclinical program studying the over-expression of ICOS

in several autoimmune diseases.

-- CXCL13 - CXCL13 is a molecule that recruits B cells into inflammatory

cell aggregates called follicles. In patients with rheumatoid arthritis

the levels of CXCL13 are elevated within the inflamed joints thus

encouraging B cells to accumulate and interact with a range of cells,

such as T cells, within the joint promoting the generation of new

inflammatory follicles and contributing to the disease process.

MedImmune has a preclinical program investigating antibodies that target CXCL13 which may have the potential to prevent the generation of these inflammatory follicles within the rheumatic joint.

The schedule for MedImmune's eight research posters to be presented at the meeting, starting on Sunday October 26, is as follows:

-- ICOS as a potential regulator in inclusion body myositis and

dermatomyositis - Chris Morehouse, M.Sc., Sunday, October 26 from 9:00

a.m. - 11:00 a.m. in Hall A, Abstract: 46

-- Internalization of the antibody (CAM-3001) following monocyte cell

surface binding to the GM-CSFR alpha chain - Brandon Higgs, Ph.D.,

Sunday, October 26 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 35

-- Neutralization of CXCL13 impacts B-cell trafficking and reduces severity

of established experimental arthritis - Matthew Sleeman, Ph.D., Monday,

October 27 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 771

-- IFN-alpha/beta as a therapeutic target in systemic lupus erythematosus,

myositis, and rheumatoid arthritis: a transcript profiling analysis of